Drugs / SGN-CD48A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03379584 | Feb 2018 → Aug 2019 | plasma cell myeloma | Seagen Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SGN-CD48A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03379584 ↗ |
| Route | Intravenous | “Intravenous (IV) infusion on days 1, 8, and 15 of a 28-day cycle” NCT03379584 ↗ |